SNX22

Across TCGA pan-cancer cohorts, SNX22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SNX22 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SNX22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNX22 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and KIRP are the cancer types where SNX22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.171	0.750	.002	18	view →
UCEC	DFS	Median	III,IV	1.000	0.541	.040	10	view →
KIRP	OS	Median	II,III,IV	0.178	0.743	.013	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SNX22–LUAD (OS)

Open the LUAD breakdown →